AstraZeneca PLC (LON:AZN) has announced its year to date and Q3 2021 results. –    Total Revenue in the year to date, including Alexion from 21 July 2021, was $25,406m, representing growth of 32% (28% at CER). Total Revenue in the third quarter increased by 50% (48% at CER) to $9,866m –    Excluding the pandemic COVID-19 … Continue reading AstraZeneca’s scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery